American Association for Cancer Research Mar 3 2025 Bottom line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, despite no prior treatment with this therapy, according to recent results from a large multidatabase analysis. Journal in which the study was published: Clinical Cancer Research , a journal of the American Association for Cancer Research (